COMPANY PROFILE

Infervision / 推想医疗

Explore full profile

AI medical imaging for screening, diagnosis, intervention and research

Chaoyang District, ChinaFounded 2016Health Tech & Medtech

Valuation $500M–1B Last recorded · 2021

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Infervision / 推想医疗

Infervision (推想医疗) is a Beijing-based AI medical technology company founded in 2016. It develops InferRead, InferOperate, InferCare and InferScholar products that use deep learning for disease screening and diagnosis, surgical planning, patient management and medical research across lung, cardiovascular, cerebrovascular, trauma and other imaging domains. Products hold NMPA, FDA, CE, UKCA and PMDA clearances and serve hospitals in more than 30 countries. The company completed a large Series D round around 2021 and lists its China headquarters in Chaoyang District, Beijing (Ocean International Center).

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: Chaoyang District, China
Employees: 72
Open positions: None listed
Dealroom signal: 65.3/100
Industry: Health, Enterprise Software
Sub-industry: Medical Devices
Sector: Health Tech & Medtech, Oncology, Core AI, Health Diagnostics, Hard Tech, AI Applications, DT and LS, science-based
Technology: Artificial Intelligence, Big Data
Business model: SaaS
Client focus: b2b
Links: Website X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES DOther financing	Jul 2021	$139M	$556M	Qiming Venture Partners · Goldman Sachs Asset Management · Shenzhen Donghai Investment · Z-Park Fund	—
SERIES DOther financing	Dec 2020	—	—	Shenzhen Yicun Tongsheng · Z-Park Fund · Shanghai Lian Yi	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Infervision / 推想医疗 website traffic

Latest recorded traffic for Infervision / 推想医疗 is 230 monthly website visits, up 91.7% over the last three months. Infervision / 推想医疗's team declined 1.4% over the past year.

Latest monthly visits230 3-month web change+91.7% 1-year team growth-1.4%

Monthly website visitsMar 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
WMWSK MedicalWSK Medical is the first and only company that have developed and launched (CE-MDR class IIb approved) an AI solution that is able to detect and classify head and neck cancer during an endoscopy in real-time	Amsterdam, Netherlands	Operational	9	$3.3M	$2.5M
SMScreenpoint MedicalSmart AI for early breast cancer detection	Nijmegen, Netherlands	Operational
OPOptellumDeveloping an artificial intelligence software platform to support clinicians in lung cancer nodule management	Oxford, United Kingdom	Operational
VIVisieOptical Data Platform for Digital Surgery	Austin, United States	Operational
SASkin AnalyticsAI medical device for skin cancer pathways.	London, United Kingdom	Operational
LMLightpoint MedicalA medical device company developing intra-operative imaging technology that can detect cancer during surgery	Chesham, United Kingdom	Acquired
THTHERAPANACEADevotion to Innovation, Compassion for Patients, Artificial Intelligence for Cancer Care	Paris, France	Operational
SBStratagen BioProviding personalized and optimized care to patients by using a tissue oxygen sensor, treatment guidance software, and ai-enabled oxygen data engine	Cambridge, United States	Operational